Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1998-04-28
Prouty, Rebecca E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435 696, 4351723, 4241851, 530383, 930100, A61K 3800, C12P 2104, C12N 1500, C07K 14755
Patent
active
057444463
ABSTRACT:
Provided is a hybrid Factor VIII having a sequence of amino acids selected from the group of A2 domain fragments 373-540, 373-508, 445-508, 484-508, 404-508, 489-508 and 484-489 according to Seq ID NO 2 substituted with corresponding sequence of porcine or murine Factor VIII. Invention also relates to methods of treatment Factor VIII deficiency with said hybrid Factor VIII.
REFERENCES:
patent: Re32011 (1985-10-01), Zimmerman et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4757006 (1988-07-01), Toole et al.
patent: 4868112 (1989-09-01), Toole, Jr.
patent: 4965199 (1990-10-01), Capon et al.
patent: 4970300 (1990-11-01), Fulton et al.
patent: 4980456 (1990-12-01), Scandella et al.
patent: 5004803 (1991-04-01), Kaufman et al.
patent: 5246850 (1993-09-01), Bennett et al.
Lollar, P. et al. (1994) "Inhibition of Human Factor VIIIa by Anti-A2 Subunit Antibodies" J. Clin. Invest. 93:2497-2504.
Gilles, Jean Guy and N.-M. R. Saint-Remy (1994) "Healthy Subjects Produce both Anti-Factor VIII and Specific Anti-Idiotype Antibodies" J. Clin. Invest, 94:1496-1505.
Hoyer, L.W. and D. Scandella (1994) "Factor VIII Inhibitors: Structure and Function in Autoantibody and Hemophilia A Patients" Seminars in Hematology 31(2)(4):1-5.
Hoeben, R.C. (1990) "Expression of Functional Factor VIII In Primary Human Skin Fibroblasts after Retrovirus-medicated Gene Transfer" J. Biol. Chem. 265(13):7318-7323.
Pittman, D.D., et al., (1992) "A2 Domain of Human Recombinant-Derived Factor VIII is Required for Procoagulant Activity but not for Thrombin Cleavage," Blood 79(2):389-397.
Brinkhouse, K.M. et al., (1985) "Purified Human Factor VIII Procoagulant Protein: Comparative Hemostatic Resonce After Infusions into Hemophilia and von Willebrand Disease Dogs," Proc. Natl. Acad, Sci. U.S.A., 82:8752-8755.
Elder, B., et al. (1993) "Sequence of the Murine Factor VIII cDNA," Genomics 16(2):374-379.
Hoeben, R.C. et al. (1993) "Toward Gene Therapy for Hemophilia A: Long-Term Persistence for Factor VIII-Secreting Fibroblasts After Transplantation into Immunodeficient Mice," Human Gene Therapy, 4(2):179-186.
Horn, R.M., et al. (1993) "Gene Splicing by Overlap Extension," Meth. Enzymol 217:270.
Levinson, B. et al. (1992) "Sequence of the Human Factor VIII-Associated Gene is Conserved in Mouse," Genomics 13:862-865.
Lollar, P., et al. (1993) "Inhibition of Human Factor VIIIa by Anti-A2 Subunit Antibodies," Blood 82:Abstracts No. 230.
Lollar, P., et al. (1992) "Coagulant Properties of Hybrid Human-Porcine Factor VIII Molecules," J. Biol. Chem. 267:23652-23657.
Lubin, I.M., et al. (1994) "Elimination of a Malor Inhibitor Epitope In Factor VIII," J. Biol. Chem. 269(12):8639-8641.
Lubin, L.M., et al. (1993) "Expression of a Recombinant Hybrid Human/Porcine Factor VIII Molecule with Elimination of Reactivity Toward an Inhibitory Anti-Human A2 Domain Antibody," Blood 82:Abstract 229.
Lusher, J.M., et al. (1993) "Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A," New Engl. J. Med., 328(7):453-459.
Rebemtulla, A., (1993) Improved Procoagulant Activity of Human Factor VIII Molecules Containing Portions of Porcine Sequence, Blood 82:Abstract 1339.
Sarkar, G., et al. (1989) "Access to a Messenger RNA Sequence or its Protein Product is not limited by Tissue or Species Specificity," Science 244:331-334.
Shima, M., et al., (1993) "Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Binding to von Willebrand Factor and to Phosphatidyl Serine," Thromb. Haemostas 69:240-246.
Scandella, D., et al. (1989) "Localization of Epitopes for Human Factor VIII Inhibitor Antibodies by Immunoblotting and Antibody Neutralization," Chem. Abst. 570, 111(25) Abstract 230240.
Scandella, D., et al. (1993) "Localization of Epitopes for Human Factor VIII Inhibitor Antibodies by Immunoblotting and Antibody Neutralization," Blood 82(6):1767-1775.
Scandella, D., et al. (1993) "A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies that Bind to A2," Chem. Abst. 782, 121(19) Abstract 268801.
Scandella, D., et al. (1989) "A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies that Bind to A2," Blood 74(5) 1618-1626.
Arai, M., et al., "Molecular basis of factor VIII by human antobodies," 863 J. Clin. Invest. 1978-1984 (1989).
Burke, R.L., et al., "The functional domains of coaqulation factor VIII:C," 261 J. Biol. Chem. 12574-12578 (1986).
Eaton, D., "Proteolytic processing of human factor VIII, Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity," 25 Biochem, 505-512 (1986).
Eaton, D.L., et al., "Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule," 25 Biochem. 8343-8347 (1986).
Eaton, D.L., et al., "Characterization of recombinant human factor VIII," 262 J. of Biol. Chem. 3285-3290 (1987).
Fass, D.N., et al., "Monoclonal antibodies to porcine factor VIII coagulant and their use in the Isolation of active coagulant protein," 59 Blood 594-600 (1982).
Fay, P.J., et al., "The size of human factor VIII heterodimers and the effects produced by thromblin," 871 Blochimica et Biophysica Acta 268-278 (1986).
Fay, P.J., "Subunit structure of thrombin-activated human factor VIIIa," 952 Biochlmica et Biophysica Acta 181-190 (19871).
Fay, P.J., "Reconstitution of human factor VIII from Isolated subunits," 262 Arch. Biochem. Biophys. 525-531 (1988).
Fay, P.J., et al., "Topography of the human factor VIII-von Willebrand factor complex," 265 J. Biol. Chem. 6197-6202 (1990).
Fay, P.J., et al., "von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation," 266 J. Biol. Chem. 2172-2177 (1991).
Fay, P.J., et al., "Human factor VIII. subunit structure," 266 J. Biol. Chem. 1-6 (1991).
Fulcher, C.A., and T.S. Zimmerman, "Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody," 79 Proc. Nat'l. Acad. Sci. U.S.A. 1648-1652 (1982).
Fulcher, C.A., et al., "Human factor VIII procoagulant protein," 76 J. Clin. Invest. 117-124 (1985).
Gitschier, J.,et al., "Characterization of the human factor VIII gene," 312 Nature 326-330 (1984).
Hill-Eubanks, D.C., and P. Lollar, "von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain," 265 J. Biol. Chem. 17854-17858 (1990).
Kaufman, R.J., et al., "Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells," 263 J. Biol. Chem. 6352-6362 (1988).
Kaufman, R.J., et al., "Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells," 9 Molec. Cell. Biol. 1233-1242 (1989).
Koedam, J.A., et al., "The effect of von Willebrand factor on activation of factor VIII by factor Xa," 189 Eur. J. Biochem. 229-234 (1990).
Kohn, D.B., and P.W. Kantoff,"Potential applications of gene therapy," 29 Transfusion 812-820 (1989).
Leyte, A., "Sulfation of Tyr.sup.100 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor," 266 J. Biol. Chem. 740-746 (1991).
Lollar, P., et al., "Activation of porcine factor VIII:C by thrombin and factor Xa," 24 Biochemistry 8056-8064 (1985).
Lollar, P. (J.S.), et al., "Association of the factor VIII light chain with von Willebrand factor," 263 J. Biol. Chem. 10451 (1988).
Lollar, P.(J.S.), et al., "Molecular characterization of commercial porcine factor VIII concentrate,"71 Blood 137-143 (1988).
Lollar, P. (J.S.), and C.G. Parker,"Subunit structure of thrombin-activated porcine factor VIII," 28 Biochemistry 666-674 (1989).
Lollar, P., and C.G. Parker,"pH-dependent denaturation of thrombin-activated porcine factor VIII," 265 J. Biol. Chem. 1688-1692 (1990).
Lollar, P., "The association of factor VIII with von Willebrand factor," 66 Mayo Clin. Proc. 542-534 (1991).
Lollar, P., and E.T. Parker, "Struct
Lollar John S.
Runge Marschall S.
Emory University
Prouty Rebecca E.
Slobodyansky Elizabeth
LandOfFree
Hybrid human/animal factor VIII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid human/animal factor VIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid human/animal factor VIII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532009